Mirtazapine for the Treatment of Methamphetamine Use among Individuals Receiving Medication for Opioid Use Disorders
Contemporary Clinical Trials Communications · 2026-11 · 101712
DOI: 10.1016/j.conctc.2026.101712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials Communications, 2026-11. Verfasst von Paola Palombo und 12 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The concurrent use of opioids and methamphetamine, recognized as the “fourth wave” of the opioid crisis in the United States, poses an urgent public health challenge. This pattern of co-use is linked to heightened psychiatric comorbidities, poor treatment adherence, severe sleep disturbances, and elevated overdose mortality. Mirtazapine, an atypical antidepressant that enhances serotonergic and noradrenergic neurotransmission, has shown promise in reducing stimulant use, improving sleep quality, and alleviating withdrawal symptoms. However, its therapeutic potential in individuals with co-occurring opioid use disorder (OUD) and methamphetamine use disorder (MUD) has not yet been evaluated.
Methods
This Phase 2 randomized, double-blind, placebo-controlled clinical trial (NCT05181891) will be conducted at Washington State University, Spokane, United States. Sixty adults receiving methadone or buprenorphine/naloxone for OUD, with toxicologically confirmed methamphetamine use, will be randomized (1:1) to receive either mirtazapine (target dose: 45 mg/day) or placebo for 10 weeks. All participants will receive Contingency Management (CM) to support medication adherence, monitored using the Medication Event Monitoring System (MEMS). The primary outcome is biochemically verified methamphetamine use. Secondary outcomes include medication adherence, sleep quality, and treatment safety and tolerability.
Conclusions
This trial will provide controlled data on the efficacy and safety of mirtazapine in individuals with co-occurring OUD and MUD. Results may inform integrated therapeutic strategies targeting stimulant use and sleep disturbances in this high-risk population.
Trial registration
ClinicalTrials.gov Identifier: NCT06323837. Registered 21 March 2024, https://clinicaltrials.gov/study/NCT06323837 .
Zitieren
APA
Palombo, P., Ryan, R., Akana, N., Schmidt, A., Hovland, S., Stark, B. C., Rodin, N., Layton, M., Roll, J. M., Grant, D. A., Smith, C. L., Miguel, A. C., & McPherson, S. (2026). Mirtazapine for the Treatment of Methamphetamine Use among Individuals Receiving Medication for Opioid Use Disorders. Contemporary Clinical Trials Communications, 101712. https://doi.org/10.1016/j.conctc.2026.101712
Vancouver
Palombo P, Ryan R, Akana N, Schmidt A, Hovland S, Stark BC, et al. Mirtazapine for the Treatment of Methamphetamine Use among Individuals Receiving Medication for Opioid Use Disorders. Contemporary Clinical Trials Communications. 2026:101712. doi:10.1016/j.conctc.2026.101712
BibTeX
@article{Palombo2026,
author = {Palombo, Paola and Ryan, Rachel and Akana, Nicole and Schmidt, Alex and Hovland, Sean and Stark, B. Connor and Rodin, Nicole and Layton, Matthew and Roll, John M. and Grant, Devon A. and Smith, Crystal L. and Miguel, André Constantino and McPherson, Sterling},
title = {Mirtazapine for the Treatment of Methamphetamine Use among Individuals Receiving Medication for Opioid Use Disorders},
journal = {Contemporary Clinical Trials Communications},
year = {2026},
pages = {101712},
doi = {10.1016/j.conctc.2026.101712}
}
EUVIMED